Lise Mørkved Helsingen

• Halvorsen, Natalie Grace Mosteiro; Hassan, Cesare; Correale, Loredana; Pilonis, Nastazja Dagny; Helsingen, Lise Mørkved & Spadaccini, Marco [Vis alle 14 forfattere av denne artikkelen] (2025). Benefits, burden, and harms of computer aided polyp detection with artificial intelligence in colorectal cancer screening: microsimulation modelling study. BMJ Medicine. 4(1). doi: 10.1136/bmjmed-2025-001446. Fulltekst i vitenarkiv
• Högdén, Amanda; Perrin, Vera; Adami, Hans Olov; Kalager, Mette; Jess, Tine & Ye, Weimin [Vis alle 10 forfattere av denne artikkelen] (2025). Temporal trends in surgical treatment of inflammatory bowel disease following introduction of biological drugs in Norway and Sweden. BMJ open gastroenterology. 12(1). doi: 10.1136/bmjgast-2025-001828. Fulltekst i vitenarkiv
• Young, Jessica C.; Helsingen, Lise Mørkved; Refsum, Erle; Högdén, Amanda; Perrin, Vera & Løberg, Magnus [Vis alle 20 forfattere av denne artikkelen] (2025). Temporal trends in characteristics and management of inflammatory bowel disease. Scandinavian Journal of Gastroenterology. ISSN 0036-5521. 60(5), s. 421–429. doi: 10.1080/00365521.2025.2478166. Fulltekst i vitenarkiv Vis sammendrag

  Background and aims: Inflammatory bowel disease (IBD) requires complex clinical management. Despite substantial advancements in endoscopy and in pharmacotherapies for patients with IBD, it remains unclear how these developments have influenced IBD incidence and clinical care. We aim to describe changes in diagnostic and therapeutic practices in IBD management. Methods: All individuals diagnosed with IBD between 1987 and 2016 were identified from nationwide registries in Norway and Sweden. We performed detailed chart abstractions for a random sample of the cohort. We describe patient characteristics, disease extent, endoscopic practices, pathology diagnostics, pharmacological therapy and surgical management, stratifying by Crohn’s disease (CD) and ulcerative colitis [UC], comparing patients diagnosed before (pre-biologic period, 1987–1999), and after the introduction of biologic drugs (biologic period, 2000–2016). Results: Chart abstraction was completed for 791 individuals (UC: 58.8%, Crohn’s disease: 40.2%, unclassified IBD: 1.0%). Comparing the biologic period to the pre-biologic period, we observed an increase in endoscopies after diagnosis, more frequent colonoscopies, and a decrease in colon resection rates. Among those diagnosed in 2007 or later compared with those diagnosed between 2000 and 2006, there was a higher treatment initiation rate of azathioprine, infliximab and adalimumab within 1 year after diagnosis. Conclusions: Our findings suggest a shift towards more frequent endoscopy, increased use of immunosuppressants and biologics, and decreased colon resection rates in recent periods.

• Foroutan, Farid; Vandvik, Per Olav; Helsingen, Lise Mørkved; Kalager, Mette; Rutter, Matt & Selby, Kevin [Vis alle 26 forfattere av denne artikkelen] (2025). Computer aided detection and diagnosis of polyps in adult patients undergoing colonoscopy: a living clinical practice guideline. The BMJ. doi: 10.1136/bmj-2024-082656. Fulltekst i vitenarkiv
• Zeng, Linan; Helsingen, Lise Mørkved; Bretthauer, Michael; Agoritsas, Thomas; Vandvik, Per Olav & Mustafa, Reem A. [Vis alle 15 forfattere av denne artikkelen] (2023). A novel framework for incorporating patient values and preferences in making guideline recommendations: guideline panel surveys. Journal of Clinical Epidemiology. ISSN 0895-4356. doi: 10.1016/j.jclinepi.2023.07.003. Fulltekst i vitenarkiv
• Langeland, Eline Aurvoll; Pisani, Synne E. R.; Kalager, Mette; Bretthauer, Michael & Helsingen, Lise Mørkved (2023). Følger Helsedirektoratets retningslinjer internasjonale standarder for troverdighet? Tidsskrift for Den norske legeforening (Tidsskriftet). ISSN 0029-2001. 143(14). doi: 10.4045/tidsskr.23.0110. Fulltekst i vitenarkiv Vis sammendrag

  BAKGRUNN - Helsedirektoratet produserer nasjonale faglige retningslinjer for helsetjenesten, og utviklingen av retningslinjene skal følge internasjonale standarder for troverdighet. Vi undersøkte om standardene blir fulgt.<p> <p>MATERIALE OG METODE - Vi benyttet skåringsverktøyet National Guideline Clearinghouse Extent of Adherence to Trustworthy Standards Instrument (NEATS), og vurderte ett tilfeldig valgt kapittel fra nasjonale faglige retningslinjer publisert eller oppdatert fra 2013 til januar 2022. NEATS har 15 domener: tre vurderes med svaralternativene ja/nei/ukjent, og tolv vurderes på en Likert-skala fra 1 til 5, der 1 tilsvarer svært lav troverdighet og 5 utmerket troverdighet. Vurderingene ble gjort individuelt av to forfattere. Interobservatørsamsvar ble vurdert med eksakt og nært samsvar samt Cohens kappa.<p> <p>RESULTATER - Vi inkluderte 60 gjeldende retningslinjer. For ni av tolv NEATS-domener vurdert med Likert-skala var det svært lav eller lav overholdelse av standarder for troverdige retningslinjer (median skår 1 eller 2). Domenene med lavest skår (median skår 1) var «studieseleksjon», «beskrivelse av studiene og resultatene», «gradering av styrken på anbefalingene» og «ekstern høring». Domenet med høyest skår var «spesifikk og utvetydig formulering av anbefalingene» (median skår 4).<p> <p>FORTOLKNING - Flertallet av de nasjonale faglige retningslinjene overholdt i liten grad standarder for troverdige retningslinjer vurdert med skåringsverktøyet NEATS.<p>

• Zeng, Linan; Li, Shelly-Anne; Yang, Mengting; Yan, Lijiao; Helsingen, Lise Mørkved & Bretthauer, Michael [Vis alle 15 forfattere av denne artikkelen] (2023). Qualitative study of guideline panelists: innovative surveys provided valuable insights regarding patient values and preferences. Journal of Clinical Epidemiology. ISSN 0895-4356. doi: 10.1016/j.jclinepi.2023.07.014. Fulltekst i vitenarkiv
• Bretthauer, Michael; Wieszczy, Paulina; Løberg, Magnus; Kamiński, Michał Filip; Werner, Tarjei Fiskergård & Helsingen, Lise Mørkved [Vis alle 10 forfattere av denne artikkelen] (2023). Estimated Lifetime Gained with Cancer Screening Tests: A Meta-Analysis of Randomized Clinical Trials. JAMA Internal Medicine. ISSN 2168-6106. 183(11), s. 1196–1203. doi: 10.1001/jamainternmed.2023.3798. Fulltekst i vitenarkiv
• Yu, Jingru; Refsum, Erle; Wieszczy, Paulina; Helsingen, Lise Mørkved; Perrin, Vera & Högdén, Amanda [Vis alle 12 forfattere av denne artikkelen] (2023). Risk of malignant lymphomas in patients with inflammatory bowel disease: a population-based cohort study. BMJ open gastroenterology. 10(1). doi: 10.1136/bmjgast-2022-001037. Fulltekst i vitenarkiv
• Jodal, Henriette C.; Wieszczy, Paulina; Klotz, Dagmar; Herfindal, Magnhild; Barua, Ishita & Tag, Petter [Vis alle 13 forfattere av denne artikkelen] (2023). A Comparison of Risk Classification Systems of Colorectal Adenomas: A Case-Cohort Study. Gastroenterology. ISSN 0016-5085. 165, s. 483–491. doi: 10.1053/j.gastro.2023.04.028. Fulltekst i vitenarkiv Vis sammendrag

  Background & Aims Because post-polypectomy surveillance uses a growing proportion of colonoscopy capacity, more targeted surveillance is warranted. We therefore compared surveillance burden and cancer detection using 3 different adenoma classification systems. Methods In a case-cohort study among individuals who had adenomas removed between 1993 and 2007, we included 675 individuals with colorectal cancer (cases) diagnosed a median of 5.6 years after adenoma removal and 906 randomly selected individuals (subcohort). We compared colorectal cancer incidence among high- and low-risk individuals defined according to the traditional (high-risk: diameter ≥10 mm, high-grade dysplasia, villous growth pattern, or 3 or more adenomas), European Society of Gastrointestinal Endoscopy (ESGE) 2020 (high-risk: diameter ≥10 mm, high-grade dysplasia, or 5 or more adenomas), and novel (high-risk: diameter ≥20 mm or high-grade dysplasia) classification systems. For the different classification systems, we calculated the number of individuals recommended frequent surveillance colonoscopy and estimated number of delayed cancer diagnoses. Results Four hundred and thirty individuals with adenomas (52.7%) were high risk based on the traditional classification, 369 (45.2%) were high risk based on the ESGE 2020 classification, and 220 (27.0%) were high risk based on the novel classification. Using the traditional, ESGE 2020, and novel classifications, the colorectal cancer incidences per 100,000 person-years were 479, 552, and 690 among high-risk individuals, and 123, 124, and 179 among low-risk individuals, respectively. Compared with the traditional classification, the number of individuals who needed frequent surveillance was reduced by 13.9% and 44.2%, respectively, and 1 (3.4%) and 7 (24.1%) cancer diagnoses were delayed using the ESGE 2020 and novel classifications. Conclusions Using the ESGE 2020 and novel risk classifications will substantially reduce resources needed for colonoscopy surveillance after adenoma removal.

• Holme, Øyvind; Kalager, Mette; Bretthauer, Michael; Adami, Hans Olov; Helsingen, Lise Mørkved & Løberg, Magnus (2023). Ongoing Trials Will Not Determine the Comparative Effectiveness of Colorectal Cancer Screening Tests. Gastroenterology. ISSN 0016-5085. 164(6), s. 856–860. doi: 10.1053/j.gastro.2020.02.071. Fulltekst i vitenarkiv
• Yu, Jingru; Refsum, Erle; Perrin, Vera; Helsingen, Lise Mørkved; Wieszczy, Paulina & Løberg, Magnus [Vis alle 11 forfattere av denne artikkelen] (2022). Inflammatory bowel disease and risk of adenocarcinoma and neuroendocrine tumors in the small bowel. Annals of Oncology. ISSN 0923-7534. s. 1–8. doi: 10.1016/j.annonc.2022.02.226. Fulltekst i vitenarkiv
• Yu, Jingru; Refsum, Erle; Helsingen, Lise Mørkved; Folseraas, Trine; Ploner, Alexander & Wieszczy, Paulina [Vis alle 15 forfattere av denne artikkelen] (2022). Risk of hepato-pancreato-biliary cancer is increased by primary sclerosing cholangitis in patients with inflammatory bowel disease: A population-based cohort study. United European Gastroenterology Journal (UEG Journal). ISSN 2050-6406. 10(2), s. 212–224. doi: 10.1002/ueg2.12204. Fulltekst i vitenarkiv Vis sammendrag

  Background There is continued uncertainty regarding the risks of hepato-pancreato-biliary cancers in patients with inflammatory bowel disease (IBD) with or without concomitant primary sclerosing cholangitis (PSC). Objective To give updated estimates on risk of hepato-pancreato-biliary cancers in patients with IBD, including pancreatic cancer, hepatocellular carcinoma, gall bladder cancer, and intra – and extrahepatic cholangiocarcinoma. Methods In a population-based cohort study, we included all patients diagnosed with IBD in Norway and Sweden from 1987 to 2016. The cohort comprised of 141,960 patients, identified through hospital databases and the National Patient Register. Participants were followed through linkage to national cancer, cause of death, and population registries. We calculated absolute risk and standardized incidence ratios (SIRs) of hepato-pancreato-biliary cancers by PSC and other clinical characteristics. Results Of the 141,960 IBD patients, 3.2% were diagnosed with PSC. During a median follow-up of 10.0 years, we identified 443 biliary tract cancers (SIR 5.2, 95% confidence interval [CI] 4.8–5.7), 161 hepatocellular carcinomas (SIR 2.4, 95% CI 2.0–2.7) and 282 pancreatic cancers (SIR 1.3, 95% CI 1.2–1.5). The relative risks were considerably higher in PSC-IBD patients, with SIR of 140 (95% CI 123–159) for biliary tract, 38.6 (95% CI 29.2–50.0) for hepatocellular, and 9.0 (95% CI 6.3–12.6) for pancreatic cancer. The SIRs were still slightly increased in non-PSC-IBD patients, compared to the general population. For biliary tract cancer, the cumulative probability at 25 years was 15.6% in PSC-IBD patients, and 0.4% in non-PSC-IBD patients. Conclusions The dramatically increased risks of hepato-pancreato-biliary cancers in PSC-IBD patients support periodic surveillance for these malignancies. While much lower, the excess relative risks in non-PSC-IBD patients were not trivial compared to non-IBD related risk factors.

• Usher-Smith, Juliet A.; Mills, Katie M.; Riedinger, Christiane; Saunders, Catherine L.; Helsingen, Lise Mørkved & Lytvyn, Lyubov [Vis alle 11 forfattere av denne artikkelen] (2021). The impact of information about different absolute benefits and harms on intention to participate in colorectal cancer screening: A think-aloud study and online randomised experiment. PLOS ONE. 16(2). doi: 10.1371/journal.pone.0246991. Fulltekst i vitenarkiv
• Jodal, Henriette C.; Klotz, Dagmar; Herfindal, Magnhild; Barua, Ishita; Tag, Petter & Helsingen, Lise Mørkved [Vis alle 12 forfattere av denne artikkelen] (2021). Long-term colorectal cancer incidence and mortality after adenoma removal in women and men. Alimentary Pharmacology and Therapeutics. ISSN 0269-2813. s. 1–10. doi: 10.1111/apt.16686. Fulltekst i vitenarkiv
• Juul, Frederik E.; Jodal, Henriette C.; Barua, Ishita; Refsum, Erle; Olsvik, Ørjan & Helsingen, Lise Mørkved [Vis alle 10 forfattere av denne artikkelen] (2021). Mortality in Norway and Sweden during the COVID-19 pandemic. Scandinavian Journal of Public Health. ISSN 1403-4948. s. 1–8. doi: 10.1177/14034948211047137. Fulltekst i vitenarkiv Vis sammendrag

  Background: Norway and Sweden are similar countries in terms of socioeconomics and health care. Norway implemented extensive COVID-19 measures, such as school closures and lockdowns, whereas Sweden did not. Aims: To compare mortality in Norway and Sweden, two similar countries with very different mitigation measures against COVID-19. <p> <p>Methods: Using real-world data from national registries, we compared all-cause and COVID-19-related mortality rates with 95% confidence intervals (CI) per 100,000 person-weeks and mortality rate ratios (MRR) comparing the five preceding years (2015–2019) with the pandemic year (2020) in Norway and Sweden. <p> <p>Results: In Norway, all-cause mortality was stable from 2015 to 2019 (mortality rate 14.6–15.1 per 100,000 person-weeks; mean mortality rate 14.9) and was lower in 2020 than from 2015 to 2019 (mortality rate 14.4; MRR 0.97; 95% CI 0.96–0.98). In Sweden, all-cause mortality was stable from 2015 to 2018 (mortality rate 17.0–17.8; mean mortality rate 17.1) and similar to that in 2020 (mortality rate 17.6), but lower in 2019 (mortality rate 16.2). Compared with the years 2015–2019, all-cause mortality in the pandemic year was 3% higher due to the lower rate in 2019 (MRR 1.03; 95% CI 1.02–1.04). Excess mortality was confined to people aged ⩾70 years in Sweden compared with previous years. The COVID-19-associated mortality rates per 100,000 person-weeks during the first wave of the pandemic were 0.3 in Norway and 2.9 in Sweden. <p> <p>Conclusions: All-cause mortality in 2020 decreased in Norway and increased in Sweden compared with previous years. The observed excess deaths in Sweden during the pandemic may, in part, be explained by mortality displacement due to the low all-cause mortality in the previous year.

• Helsingen, Lise Mørkved; Løberg, Magnus; Refsum, Erle; Gjøstein, Dagrun Kyte; Wieszczy, Paulina & Olsvik, Ørjan [Vis alle 16 forfattere av denne artikkelen] (2021). Covid-19 transmission in fitness centers in Norway - a randomized trial. BMC Public Health. 21, s. 1–9. doi: 10.1186/s12889-021-12073-0. Fulltekst i vitenarkiv Vis sammendrag

  Background: Closed fitness centers during the Covid-19 pandemic may negatively impact health and wellbeing. We assessed whether training at fitness centers increases the risk of SARS-CoV-2 virus infection.<p> <p>Methods: In a two-group parallel randomized controlled trial, fitness center members aged 18 to 64 without Covid-19-relevant comorbidities, were randomized to access to training at a fitness center or no-access. Fitness centers applied physical distancing (1 m for floor exercise, 2 m for high-intensity classes) and enhanced hand and surface hygiene. Primary outcomes were SARS-CoV-2 RNA status by polymerase chain reaction (PCR) after 14 days, hospital admission after 21 days. The secondary endpoint was SARS-CoV-2 antibody status after 1 month.<p> <p>Results: 3764 individuals were randomized; 1896 to the training arm and 1868 to the no-training arm. In the training arm, 81.8% trained at least once, and 38.5% trained ≥six times. Of 3016 individuals who returned the SARSCoV-2 RNA tests (80.5%), there was one positive test in the training arm, and none in the no-training arm (risk difference 0.053%; 95% CI − 0.050 to 0.156%; p = 0.32). Eleven individuals in the training arm (0.8% of tested) and 27 in the no-training arm (2.4% of tested) tested positive for SARS-CoV-2 antibodies (risk difference − 0.87%; 95%CI − 1.52% to − 0.23%; p = 0.001). No outpatient visits or hospital admissions due to Covid-19 occurred in either arm.<p> <p>Conclusion: Provided good hygiene and physical distancing measures and low population prevalence of SARS-CoV-2 infection, there was no increased infection risk of SARS-CoV-2 in fitness centers in Oslo, Norway for individuals without Covid-19-relevant comorbidities.

• Helsingen, Lise M.; Refsum, Erle; Gjøstein, Dagrun Kyte; Løberg, Magnus; Bretthauer, Michael & Kalager, Mette [Vis alle 7 forfattere av denne artikkelen] (2020). The COVID-19 pandemic in Norway and Sweden – threats, trust, and impact on daily life: a comparative survey. BMC Public Health. 20:1597, s. 1–10. doi: 10.1186/s12889-020-09615-3. Fulltekst i vitenarkiv Vis sammendrag

  Background Norway and Sweden have similar populations and health care systems, but different reactions to the COVID-19 pandemic. Norway closed educational institutions, and banned sports and cultural activities; Sweden kept most institutions and training facilities open. We aimed to compare peoples’ attitudes towards authorities and control measures, and perceived impact of the pandemic and implemented control measures on life in Norway and Sweden. Methods Anonymous web-based surveys for individuals age 15 or older distributed through Facebook using the snowball method, in Norway and Sweden from mid-March to mid-April, 2020. The survey contained questions about perceived threat of the pandemic, views on infection control measures, and impact on daily life. We performed descriptive analyses of the responses and compared the two countries. Results 3508 individuals participated in the survey (Norway 3000; Sweden 508). 79% were women, the majority were 30–49 years (Norway 60%; Sweden 47%), and about 45% of the participants in both countries had more than 4 years of higher education. Participants had high trust in the health services, but differed in the degree of trust in their government (High trust in Norway 17%; Sweden 37%). More Norwegians than Swedes agreed that school closure was a good measure (Norway 66%; Sweden 18%), that countries with open schools were irresponsible (Norway 65%; Sweden 23%), and that the threat from repercussions of the mitigation measures were large or very large (Norway 71%; Sweden 56%). Both countries had a high compliance with infection preventive measures (> 98%). Many lived a more sedentary life (Norway 69%; Sweden 50%) and ate more (Norway 44%; Sweden 33%) during the pandemic. Conclusion Sweden had more trust in the authorities, while Norwegians reported a more negative lifestyle during the pandemic. The level of trust in the health care system and self-reported compliance with preventive measures was high in both countries despite the differences in infection control measures.

• Helsingen, Lise M.; Zeng, Linan; Siemieniuk, Reed A.C.; Lytvyn, Lyubov; Vandvik, Per Olav & Agoritsas, Thomas [Vis alle 8 forfattere av denne artikkelen] (2020). Establishing thresholds for important benefits considering the harms of screening interventions. BMJ Open. 10:e037854(12), s. 1–9. doi: 10.1136/bmjopen-2020-037854. Fulltekst i vitenarkiv
• Zeng, Linan; Helsingen, Lise M.; Nampo, Fernando Kenji; Wang, Yuting; Yao, Linag & Siemieniuk, Reed Alexander [Vis alle 8 forfattere av denne artikkelen] (2020). How do cancer screening guidelines trade off benefits versus harms and burdens of screening? A systematic survey. BMJ Open. doi: 10.1136/bmjopen-2020-038322. Fulltekst i vitenarkiv
• Hassan, Cesare; Antonelli, Giulio; Dumonceau, Jean-Marc; Regula, Jaroslaw; Bretthauer, Michael & Chaussade, Stanislas [Vis alle 21 forfattere av denne artikkelen] (2020). Post-polypectomy colonoscopy surveillance: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2020. Endoscopy. ISSN 0013-726X. 52(8), s. 687–700. doi: 10.1055/a-1185-3109. Fulltekst i vitenarkiv
• Helsingen, Lise M.; Vandvik, Per Olav; Jodal, Henriette C.; Agoritsas, Thomas; Lytvyn, Lyubov & Anderson, Joseph C. [Vis alle 21 forfattere av denne artikkelen] (2019). Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: A clinical practice guideline. The BMJ. 367:I5515, s. 1–16. doi: 10.1136/bmj.l5515. Fulltekst i vitenarkiv Vis sammendrag

  Abstract CLINICAL QUESTION: Recent 15-year updates of sigmoidoscopy screening trials provide new evidence on the effectiveness of colorectal cancer screening. Prompted by the new evidence, we asked: "Does colorectal cancer screening make an important difference to health outcomes in individuals initiating screening at age 50 to 79? And which screening option is best?" CURRENT PRACTICE: Numerous guidelines recommend screening, but vary on recommended test, age and screening frequency. This guideline looks at the evidence and makes recommendations on screening for four screening options: faecal immunochemical test (FIT) every year, FIT every two years, a single sigmoidoscopy, or a single colonoscopy. RECOMMENDATIONS: These recommendations apply to adults aged 50-79 years with no prior screening, no symptoms of colorectal cancer, and a life expectancy of at least 15 years. For individuals with an estimated 15-year colorectal cancer risk below 3%, we suggest no screening (weak recommendation). For individuals with an estimated 15-year risk above 3%, we suggest screening with one of the four screening options: FIT every year, FIT every two years, a single sigmoidoscopy, or a single colonoscopy (weak recommendation). With our guidance we publish the linked research, a graphic of the absolute harms and benefits, a clear description of how we reached our value judgments, and linked decision aids. HOW THIS GUIDELINE WAS CREATED: A guideline panel including patients, clinicians, content experts and methodologists produced these recommendations using GRADE and in adherence with standards for trustworthy guidelines. A linked systematic review of colorectal cancer screening trials and microsimulation modelling were performed to inform the panel of 15-year screening benefits and harms. The panel also reviewed each screening option's practical issues and burdens. Based on their own experience, the panel estimated the magnitude of benefit typical members of the population would value to opt for screening and used the benefit thresholds to inform their recommendations. THE EVIDENCE: Overall there was substantial uncertainty (low certainty evidence) regarding the 15-year benefits, burdens and harms of screening. Best estimates suggested that all four screening options resulted in similar colorectal cancer mortality reductions. FIT every two years may have little or no effect on cancer incidence over 15 years, while FIT every year, sigmoidoscopy, and colonoscopy may reduce cancer incidence, although for FIT the incidence reduction is small compared with sigmoidoscopy and colonoscopy. Screening related serious gastrointestinal and cardiovascular adverse events are rare. The magnitude of the benefits is dependent on the individual risk, while harms and burdens are less strongly associated with cancer risk. UNDERSTANDING THE RECOMMENDATION: Based on benefits, harms, and burdens of screening, the panel inferred that most informed individuals with a 15-year risk of colorectal cancer of 3% or higher are likely to choose screening, and most individuals with a risk of below 3% are likely to decline screening. Given varying values and preferences, optimal care will require shared decision making.

• Jodal, Henriette C.; Helsingen, Lise M.; Anderson, Joseph C.; Lytvyn, Lyubov; Vandvik, Per Olav & Emilsson, Louise (2019). Colorectal cancer screening with faecal testing, sigmoidoscopy or colonoscopy: a systematic review and network meta-analysis. BMJ Open. 9(10), s. 1–18. doi: 10.1136/bmjopen-2019-032773. Fulltekst i vitenarkiv
• Buskermolen, Maaike; Cenin, Dayna R; Helsingen, Lise M.; Guyatt, Gordon; Vandvik, Per Olav & Haug, Ulrike [Vis alle 8 forfattere av denne artikkelen] (2019). Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study. The BMJ. 367, s. 1–11. doi: 10.1136/bmj.l5383. Fulltekst i vitenarkiv
• Juul, Frederik Emil; Garborg, Kjetil Kjeldstad; Bretthauer, Michael; Skudal, Hilde Kristin; Oines, Mari N. & Wiig, Håvard [Vis alle 16 forfattere av denne artikkelen] (2018). Fecal microbiota transplantation for primary Clostridium difficile infection. New England Journal of Medicine. ISSN 0028-4793. 378(26), s. 2535–2537. doi: 10.1056/NEJMc1803103. Fulltekst i vitenarkiv
• Siemieniuk, Reed A.C.; Harris, Ian A.; Agoritsas, Thomas; Poolman, Rudolf W.; Romina, Brignardello-Petersen & Velde, Stijn Van De [Vis alle 18 forfattere av denne artikkelen] (2017). Arthroscopic surgery for degenerative knee arthritis and meniscal tears: a clinical practice guideline. The BMJ. 357(5). doi: 10.1136/bmj.j1982. Fulltekst i vitenarkiv Vis sammendrag

  Republished clinical guideline

• Øines, Mari Nanna; Helsingen, Lise M.; Bretthauer, Michael & Emilsson, Louise (2017). Epidemiology and risk factors of colorectal polyps. Baillière's Best Practice & Research Clinical Gastroenterology. ISSN 1521-6918. 31(4), s. 419–424. doi: 10.1016/j.bpg.2017.06.004. Fulltekst i vitenarkiv

Se alle arbeider i NVA

• Kalager, Mette; Bretthauer, Michael; Graver, Hans Petter; Helsingen, Lise Mørkved; Løberg, Magnus & Nylund, Anna [Vis alle 7 forfattere av denne artikkelen] (2025). Forholdsmessighet. Medisin, juss, filosofi og pandemi. Fagbokforlaget. ISBN 9788245053555. 348 s. Fulltekst i vitenarkiv

Se alle arbeider i NVA

• Helsingen, Lise Mørkved; Langeland, Eline Aurvoll; Pisani, Synne Eline Rotihaug; Vandvik, Per Olav; Haavardsholm, Espen A. & Malt, Ulrik Fredrik [Vis alle 10 forfattere av denne artikkelen] (2024). Glansbilder av nasjonale faglige retningslinjer fra Helsedirektoratet. Tidsskrift for Den norske legeforening (Tidsskriftet). ISSN 0029-2001. 144(5). doi: 10.4045/tidsskr.24.0141. Fulltekst i vitenarkiv
• Gantzel, Rasmus; Wieszczy, Paulina; Refsum, Erle; Jess, Tine; Larsen, Lone & Bretthauer, Michael [Vis alle 11 forfattere av denne artikkelen] (2023). Prognostic models for colorectal cancer incidence and mortality in patients with inflammatory bowel disease. Cochrane Database of Systematic Reviews. doi: 10.1002/14651858.CD015434. Fulltekst i vitenarkiv
• Øverenget, Einar; Kalager, Mette; Grødeland, Gunnveig; Olsvik, Ørjan; Nylund, Anna & Løberg, Magnus [Vis alle 8 forfattere av denne artikkelen] (2022). Når smittevern blir uforståelig. Fulltekst i vitenarkiv
• Helsingen, Lise Mørkved; Løberg, Magnus; Bretthauer, Michael & Kalager, Mette (2022). Reply to: Letter to the Editor regarding "Covid-19 transmission in fitness centers in Norway-a randomized trial". BMC Public Health. 22(1), s. 2437–2437. doi: 10.1186/s12889-022-14799-x. Fulltekst i vitenarkiv
• Bretthauer, Michael; Helsingen, Lise Mørkved; Kalager, Mette; Vandvik, Per Olav; Agoritsas, Thomas & Guyatt, Gordon (2020). The future of colorectal cancer screening: Parentalism or shared decision-making? CMAJ - Canadian Medical Association Journal. ISSN 0820-3946. 192(18), s. E484–E484. doi: 10.1503/cmaj.74839. Fulltekst i vitenarkiv
• Refsum, Erle; Helsingen, Lise M.; Jodal, Henriette Cecilie; Løberg, Magnus; Høstmælingen, Njål & Kalager, Mette (2019). Personvern – en hinderløype. 139(4), s. 1–3. doi: 10.4045/tidsskr.19.0077. Fulltekst i vitenarkiv
• Helsingen, Lise M.; Vandvik, Per Olav; Jodal, Henriette C.; Murphy, Silje Bjerkelund; Heen, Anja Fog & Kalager, Mette [Vis alle 7 forfattere av denne artikkelen] (2019). Tarmkreftscreening, eller ikke? 139(15). doi: 10.4045/tidsskr.19.0323. Fulltekst i vitenarkiv
• Juul, Frederik Emil; Garborg, Kjetil Kjeldstad; Bretthauer, Michael; Kalager, Mette; Midtvedt, Tore & Furholm, Siv [Vis alle 17 forfattere av denne artikkelen] (2018). Fecal microbiota transplantation versus antibiotics for primary Clostridium difficile infection - a multicenter, randomized proof-of-concept trial. Fulltekst i vitenarkiv
• Kalager, Mette; Hagen, Eirik M. & Helsingen, Lise M. (2016). Farlig forretning på frykt. Dagens næringsliv. ISSN 0803-9372. 127(278), s. 30–30. Fulltekst i vitenarkiv
• Helsingen, Lise M. (2015). Ett år som medisinsk redaktør. Tidsskrift for Den norske legeforening (Tidsskriftet). ISSN 0029-2001. 135, s. 1335–1335. doi: 10.4045/tidsskr.15.0851. Fulltekst i vitenarkiv
• Halvorsen, Edward; Svendsen, Mats Amundsen; Vist, Live; Tromsdal, Ane Kvåle; Isaq, Sadyo Husein & Eriksrød, Mathea [Vis alle 8 forfattere av denne artikkelen] (2026). Pedagogiske tiltak for å styrke medisinstudenters håndtering av klinisk usikkerhet i ortopedisk smågruppeundervisning. Universitetet i Oslo. Fulltekst i vitenarkiv

Se alle arbeider i NVA